(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer.
The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated with chemotherapy, the companies said.
The drug belongs to a class of treatments called antibody-drug conjugates, which have often been described as “guided-missile” cancer drugs.
Patritumab deruxtecan was tested in patients with non-small cell lung cancer who had a gene mutation called EGFR. Non-small cell lung cancer is the most common form of lung cancer.
The study focused on patients who had previously received treatment with a class of drugs known as tyrosine kinase inhibitors.
(Reporting by Sriparna Roy and Kashish Tandon in Bengaluru; Editing by Tasim Zahid)
Source link : https://www.medscape.com/s/viewarticle/daiichi-sankyo-mercks-cancer-drug-meets-main-goal-late-stage-2024a1000gu0?src=rss
Author :
Publish date : 2024-09-17 10:11:03
Copyright for syndicated content belongs to the linked Source.